Compare FBIZ & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FBIZ | PRLD |
|---|---|---|
| Founded | 1909 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.7M | 529.1M |
| IPO Year | 2012 | 2020 |
| Metric | FBIZ | PRLD |
|---|---|---|
| Price | $69.46 | $3.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $78.80 | $9.20 |
| AVG Volume (30 Days) | 43.9K | ★ 443.0K |
| Earning Date | 10-29-2026 | 11-11-2026 |
| Dividend Yield | ★ 1.93% | N/A |
| EPS Growth | 14.23 | ★ 23.21 |
| EPS | ★ 3.28 | N/A |
| Revenue | N/A | ★ $12,140,000.00 |
| Revenue This Year | $9.80 | $258.83 |
| Revenue Next Year | $7.57 | N/A |
| P/E Ratio | $21.53 | ★ N/A |
| Revenue Growth | N/A | ★ 73.43 |
| 52 Week Low | $46.07 | $1.16 |
| 52 Week High | $73.74 | $6.83 |
| Indicator | FBIZ | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 45.24 | 36.85 |
| Support Level | $67.54 | $3.40 |
| Resistance Level | $73.61 | $4.10 |
| Average True Range (ATR) | 1.37 | 0.27 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 50.63 | 23.90 |
First Business Financial Services Inc operates as a bank holding company. The Bank operates as a business bank, delivering a full line of commercial banking products, including commercial loans and commercial real estate loans, to meet the specific needs of small and medium-sized businesses, business owners, executives, professionals, and high-net-worth individuals. The company's products and services include commercial lending, SBA lending and servicing, asset-based lending, equipment financing, factoring, trust, and investment services, treasury management services, and a broad range of deposit products. Geographically, all the business activity functioned through the region of the United States.
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.